These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35080118)

  • 1. Overcoming STING Agonists Barriers: Peptide, Protein, and Biomembrane-based Biocompatible Delivery Strategies.
    Zheng YF; Wu JJ
    Chem Asian J; 2022 Mar; 17(6):e202101400. PubMed ID: 35080118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
    Wu JJ; Zhao L; Hu HG; Li WH; Li YM
    Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
    Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
    ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives.
    Huang C; Shao N; Huang Y; Chen J; Wang D; Hu G; Zhang H; Luo L; Xiao Z
    Mater Today Bio; 2023 Dec; 23():100839. PubMed ID: 38024837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
    Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
    Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
    Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination.
    Chattopadhyay S; Hu CJ
    Nanomedicine (Lond); 2020 Dec; 15(29):2883-2894. PubMed ID: 33252301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy.
    Zhou Q; Zhou Y; Li T; Ge Z
    Macromol Biosci; 2021 Aug; 21(8):e2100133. PubMed ID: 34117839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
    Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
    Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING-Activating Small Molecular Therapeutics for Cancer Immunotherapy.
    Huang C; Tong T; Ren L; Wang H
    Chembiochem; 2024 Oct; 25(19):e202400255. PubMed ID: 38980259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfonated Perylene as Three-in-One STING Agonist for Cancer Chemo-Immunotherapy.
    Zhao X; Zheng R; Zhang B; Zhao Y; Xue W; Fang Y; Huang Y; Yin M
    Angew Chem Int Ed Engl; 2024 Mar; 63(11):e202318799. PubMed ID: 38230819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Ziyuglycoside II from a Natural Products Library as a STING Agonist.
    Cui X; Xie Y; Zhang M; Gao J; Zhou X; Ding J; Cen S; Zhou J
    ChemMedChem; 2022 Jun; 17(11):e202100719. PubMed ID: 35293138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
    Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
    Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of small molecule inhibitors/agonists targeting STING for disease.
    Liu K; Lan Y; Li X; Li M; Cui L; Luo H; Luo L
    Biomed Pharmacother; 2020 Dec; 132():110945. PubMed ID: 33254439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation.
    Ji N; Wang M; Tan C
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a STING Agonist and Photothermal Therapy Using Chitosan Hydrogels for Cancer Immunotherapy.
    Chen C; Hu M; Cao Y; Zhu B; Chen J; Li Y; Shao J; Zhou S; Shan P; Zheng C; Li Z; Li Z
    Biomacromolecules; 2023 Jun; 24(6):2790-2803. PubMed ID: 37125731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
    Garland KM; Sheehy TL; Wilson JT
    Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Non-Nucleotide Small-Molecule STING Agonists
    Cherney EC; Zhang L; Lo J; Huynh T; Wei D; Ahuja V; Quesnelle C; Schieven GL; Futran A; Locke GA; Lin Z; Monereau L; Chaudhry C; Blum J; Li S; Fereshteh M; Li-Wang B; Gangwar S; Pan C; Chong C; Zhu X; Posy SL; Sack JS; Zhang P; Ruzanov M; Harner M; Akhtar F; Schroeder GM; Vite G; Fink B
    J Med Chem; 2022 Feb; 65(4):3518-3538. PubMed ID: 35108011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING, a promising target for small molecular immune modulator: A review.
    Liu Y; Lu X; Qin N; Qiao Y; Xing S; Liu W; Feng F; Liu Z; Sun H
    Eur J Med Chem; 2021 Feb; 211():113113. PubMed ID: 33360799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pam
    Hu HG; Wu JJ; Zhang BD; Li WH; Li YM
    Bioconjug Chem; 2020 Nov; 31(11):2499-2503. PubMed ID: 33147965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.